PARP Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leading Players Wheeling the Therapeutics Landscape
August 01, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- PARP Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leading Players Wheeling the...
DNA Repair Drugs Market to Grow at 6.5% CAGR, Touching US$ 10.4 Bn by 2031: TMR Study
July 05, 2023 07:15 ET
|
Transparency Market Research
Wilmington, Delaware, United States, July 05, 2023 (GLOBE NEWSWIRE) -- The global DNA repair drugs market was valued at US$ 5.9 Bn in 2022 and is projected to reach US$ 10.4 Bn by 2031 with CAGR of...
PCSK9 Inhibitors Market Sales to expand at a 15.8% CAGR from 2023 to 2033, Repatha-based Inhibitors to be Most Widely Used: Future Market Insights, Inc.
January 11, 2023 11:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Jan. 11, 2023 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global PCSK9 inhibitors market to augment at a 15.8% CAGR from 2022 to 2032. By the end of the said...
The DNA damage response (DDR) targeting therapeutics market is projected to be worth USD 1.07 billion in 2030, growing at an annualized rate of 52.6% during the period 2024-2030, claims Roots Analysis
September 08, 2021 09:00 ET
|
Roots Analysis
London, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “DNA Damage Response Targeting Therapeutics (beyond PARP inhibitors) Market, 2021-2030” report to its list of...
Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019
April 01, 2019 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
September 10, 2018 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...